Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction

Developing physiologically-based pharmacokinetic (PBPK) models for chemicals can be resource-intensive, as neither chemical-specific parameters nor in vivo pharmacokinetic data are easily available for model construction. Previously developed, well-parameterized, and thoroughly-vetted models can be a great resource for the construction of models pertaining to new chemicals. A PBPK knowledgebase was compiled and developed from existing PBPK-related articles and used to develop new models. From 2,039 PBPK-related articles published between 1977 and 2013, 307 unique chemicals were identified for use as the basis of our knowledgebase. Keywords related to species, gender, developmental stages, and organs were analyzed from the articles within the PBPK knowledgebase. A correlation matrix of the 307 chemicals in the PBPK knowledgebase was calculated based on pharmacokinetic-relevant molecular descriptors. Chemicals in the PBPK knowledgebase were ranked based on their correlation toward ethylbenzene and gefitinib. Next, multiple chemicals were selected to represent exact matches, close analogues, or non-analogues of the target case study chemicals. Parameters, equations, or experimental data relevant to existing models for these chemicals and their analogues were used to construct new models, and model predictions were compared to observed values. This compiled knowledgebase provides a chemical structure-based approach for identifying PBPK models relevant to other chemical entities. Using suitable correlation metrics, we demonstrated that models of chemical analogues in the PBPK knowledgebase can guide the construction of PBPK models for other chemicals.

[1]  Robert P. Sheridan,et al.  Chemical Similarity Using Physiochemical Property Descriptors , 1996, J. Chem. Inf. Comput. Sci..

[2]  M E Andersen,et al.  Mode-of-action-based dosimeters for interspecies extrapolation of vinyl acetate inhalation risk. , 2001, Inhalation toxicology.

[3]  Harvey J Clewell,et al.  Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling , 2007, Journal of Exposure Science and Environmental Epidemiology.

[4]  Robert C. Glen,et al.  Cytochrome P450 site of metabolism prediction from 2D topological fingerprints using GPU accelerated probabilistic classifiers , 2014, Journal of Cheminformatics.

[5]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.

[6]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[7]  George Chang,et al.  Assessment of in silico models for fraction of unbound drug in human liver microsomes , 2010, Expert opinion on drug metabolism & toxicology.

[8]  C J Portier,et al.  Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II. Rates of metabolism. , 1998, Toxicology and applied pharmacology.

[9]  Jeffrey W Fisher,et al.  Pharmacokinetic modeling: prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. , 2011, Toxicology and applied pharmacology.

[10]  S. Pierson,et al.  Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[11]  M Rowland,et al.  Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. , 2001, Antisense & nucleic acid drug development.

[12]  David Ashley,et al.  Dermal, oral, and inhalation pharmacokinetics of methyl tertiary butyl ether (MTBE) in human volunteers. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  Tycho Heimbach,et al.  Prodrugs: design and clinical applications , 2008, Nature Reviews Drug Discovery.

[14]  H J Clewell,et al.  Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. , 1991, Toxicology and applied pharmacology.

[15]  Harvey J. Clewell,et al.  Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  Jan Snoeys,et al.  From preclinical to human – prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example , 2012, Biopharmaceutics & drug disposition.

[17]  J Meulenbelt,et al.  A population physiologically based pharmacokinetic/pharmacodynamic model for the inhibition of 11-beta-hydroxysteroid dehydrogenase activity by glycyrrhetic acid. , 2001, Toxicology and applied pharmacology.

[18]  Irini Doytchinova,et al.  Quantitative structure--plasma protein binding relationships of acidic drugs. , 2012, Journal of pharmaceutical sciences.

[19]  K Krishnan,et al.  A Spreadsheet Program for Modeling Quantitative Structure-Pharmacokinetic Relationships for Inhaled Volatile Organics in Humans , 2005, SAR and QSAR in environmental research.

[20]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[21]  Rocky Goldsmith,et al.  Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment. , 2012, Reviews of environmental contamination and toxicology.

[22]  J. Gallo,et al.  Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib , 2009, Molecular Cancer Therapeutics.

[23]  Curtis C Dary,et al.  A physiologically based pharmacokinetic/pharmacodynamic model for carbofuran in Sprague-Dawley rats using the exposure-related dose estimating model. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  Ryo Shimizu,et al.  QSAR application for the prediction of compound permeability with in silico descriptors in practical use , 2009, J. Comput. Aided Mol. Des..

[25]  R B Conolly,et al.  Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments. , 1995, Toxicology letters.

[26]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[27]  Tudor I. Oprea,et al.  Quantifying the Relationships among Drug Classes , 2008, J. Chem. Inf. Model..

[28]  P L Bonate,et al.  Preliminary physiologically based pharmacokinetic model for cocaine in the rat: model development and scale-up to humans. , 1996, Journal of pharmaceutical sciences.

[29]  Franco Lombardo,et al.  Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance , 2013, Journal of clinical pharmacology.

[30]  C DeRosa,et al.  Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. , 1997, Toxicology and applied pharmacology.

[31]  Melvin E. Andersen,et al.  Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropyfluorophosphate , 1990 .

[32]  R Tardif,et al.  A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[33]  L Aarons,et al.  Population pharmacokinetics. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[34]  Michael-Rock Goldsmith,et al.  A pharmacokinetic model of cis- and trans-permethrin disposition in rats and humans with aggregate exposure application. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[35]  R Tardif,et al.  Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. , 2000, Toxicology and applied pharmacology.

[36]  Franco Lombardo,et al.  Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State , 2013, Journal of clinical pharmacology.

[37]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[38]  K Krishnan,et al.  An algorithm for predicting tissue: blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data. , 1995, Journal of toxicology and environmental health.

[39]  Corie A Ellison,et al.  Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion. , 2011, Toxicology.

[40]  Yu-Mei Tan,et al.  Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[41]  Ronald E. Baynes,et al.  Carcass Vcarcass Vliver Vkidney Ccarcass Cliver Vplasma Cplasma Ckidney Qcarcass Qtot Carterial Qliver Qkidney Liver Kidney Urine Plasma IV Dose PO Dose LiverStomach , 2008 .

[42]  Trevor N Brown,et al.  General model for estimating partition coefficients to organisms and their tissues using the biological compositions and polyparameter linear free energy relationships. , 2013, Environmental science & technology.

[43]  E. Hubal,et al.  Exposure-based prioritization of chemicals for risk assessment , 2011 .

[44]  Jeffery M Gearhart,et al.  Predicting passive and active tissue:plasma partition coefficients: interindividual and interspecies variability. , 2014, Journal of pharmaceutical sciences.

[45]  Kairui Feng,et al.  The Simcyp Population Based Simulator: Architecture, Implementation, and Quality Assurance , 2013, In Silico Pharmacology.

[46]  S. Agatonovic-Kustrin,et al.  Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. , 2000, Journal of pharmaceutical and biomedical analysis.

[47]  Vijay K. Gombar,et al.  Quantitative Structure − Activity Relationship Models of Clinical Pharmacokinetics : Clearance and Volume of Distribution , 2013 .

[48]  Daniel T. Chang,et al.  DockScreen: A Database of In Silico Biomolecular Interactions to Support Computational Toxicology , 2014 .

[49]  Markus J. Herrgård,et al.  Network-based prediction of human tissue-specific metabolism , 2008, Nature Biotechnology.

[50]  Jeffrey W Fisher,et al.  Prediction and evaluation of route dependent dosimetry of BPA in rats at different life stages using a physiologically based pharmacokinetic model. , 2013, Toxicology and applied pharmacology.

[51]  Paul S Price,et al.  Application of a source-to-outcome model for the assessment of health impacts from dietary exposures to insecticide residues. , 2011, Regulatory toxicology and pharmacology : RTP.

[52]  Patrick Bultinck,et al.  Quantum Similarity Superposition Algorithm (QSSA): A Consistent Scheme for Molecular Alignment and Molecular Similarity Based on Quantum Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[53]  C B Frederick,et al.  Application of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper airways. , 1998, Toxicology and applied pharmacology.

[54]  R Tardif,et al.  Physiologically based modeling of p‐tert‐octylphenol kinetics following intravenous, oral or subcutaneous exposure in male and female Sprague–Dawley rats , 2010, Journal of applied toxicology : JAT.

[55]  Melvin E Andersen,et al.  Route-specific differences in distribution characteristics of octamethylcyclotetrasiloxane in rats: analysis using PBPK models. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[56]  Anthony J Williams,et al.  Public chemical compound databases. , 2008, Current opinion in drug discovery & development.

[57]  S M Hays,et al.  A proposed approach to study the toxicology of complex mixtures of petroleum products: the integrated use of QSAR, lumping analysis and PBPK/PD modeling. , 1997, Environmental health perspectives.

[58]  G. Csanády,et al.  The relevance of physical activity for the kinetics of inhaled gaseous substances , 2000, Archives of Toxicology.

[59]  A Vinegar,et al.  Setting safe acute exposure limits for halon replacement chemicals using physiologically based pharmacokinetic modeling. , 2000, Inhalation toxicology.

[60]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.

[61]  R Tardif,et al.  Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. , 1997, Toxicology and applied pharmacology.

[62]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[63]  Melvin E Andersen,et al.  PBPK modeling of complex hydrocarbon mixtures: gasoline. , 2004, Environmental toxicology and pharmacology.

[64]  John Cocker,et al.  Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP). , 2004, Toxicology letters.

[65]  Andreas Bender,et al.  Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms , 2012, J. Chem. Inf. Model..

[66]  Stefan Willmann,et al.  Theoretical Biology and Medical Modelling Open Access Dynamically Simulating the Interaction of Midazolam and the Cyp3a4 Inhibitor Itraconazole Using Individual Coupled Whole-body Physiologically-based Pharmacokinetic (wb-pbpk) Models , 2022 .

[67]  Kannan Krishnan,et al.  Molecular Structure-Based Prediction of the Partition Coefficients of Organic Chemicals for Physiological Pharmacokinetic Models , 1996 .

[68]  Donald E Mager,et al.  Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[69]  Jianzhong Liu,et al.  Prediction and mechanistic interpretation of human oral drug absorption using MI-QSAR analysis. , 2007, Molecular pharmaceutics.

[70]  R. Tardif,et al.  Comparison of the influence of binary mixtures versus a ternary mixture of inhaled aromatic hydrocarbons on their blood kinetics in the rat , 1996, Archives of Toxicology.

[71]  Walter Schmitt,et al.  General approach for the calculation of tissue to plasma partition coefficients. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[72]  A W Kelman,et al.  Population Pharmacokinetics Theory and Clinical Application , 1986, Clinical pharmacokinetics.

[73]  Rebecca A Clewell,et al.  Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: a physiologically-based pharmacokinetic analysis of perchlorate and iodide kinetics in the rat. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[74]  P N Judson,et al.  Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.

[75]  H J Clewell,et al.  Pharmacodynamic model of the rat estrus cycle in relation to endocrine disruptors. , 1997, Journal of toxicology and environmental health.

[76]  Thomas Peyret,et al.  A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. , 2010, Toxicology and applied pharmacology.

[77]  Rogelio Tornero-Velez,et al.  Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. , 2010, Toxicology and applied pharmacology.

[78]  G Beck,et al.  Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. , 2001, Journal of pharmaceutical sciences.

[79]  C W Yap,et al.  Regression methods for developing QSAR and QSPR models to predict compounds of specific pharmacodynamic, pharmacokinetic and toxicological properties. , 2007, Mini reviews in medicinal chemistry.

[80]  Johann Gasteiger,et al.  Ligand-Based Models for the Isoform Specificity of Cytochrome P450 3A4, 2D6, and 2C9 Substrates , 2007, J. Chem. Inf. Model..

[81]  C. Tappert,et al.  A Survey of Binary Similarity and Distance Measures , 2010 .

[82]  Lisa M Sweeney,et al.  Development of a physiologically based pharmacokinetic (PBPK) model for methyl iodide in rats, rabbits, and humans , 2009, Inhalation toxicology.

[83]  J. Heider,et al.  Ethylbenzene Dehydrogenase, a Novel Hydrocarbon-oxidizing Molybdenum/Iron-Sulfur/Heme Enzyme* , 2001, The Journal of Biological Chemistry.

[84]  Atsushi Kambayashi,et al.  Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[85]  H. B. Matthews,et al.  Using Structural Information to Create Physiologically Based Pharmacokinetic Models for All Polychlorinated Biphenyls: I. Tissue:Blood Partition Coefficients , 1997 .

[86]  Rebecca A Clewell,et al.  PBPK predictions of perchlorate distribution and its effect on thyroid uptake of radioiodide in the male rat. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[87]  Darren R. Flower,et al.  On the Properties of Bit String-Based Measures of Chemical Similarity , 1998, J. Chem. Inf. Comput. Sci..

[88]  Josiah C. Hoskins,et al.  Artificial neural network models for knowledge representation in chemical engineering , 1990 .

[89]  F. Theil,et al.  A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.

[90]  Dolores Diaz,et al.  An algorithm for evaluating potential tissue drug distribution in toxicology studies from readily available pharmacokinetic parameters. , 2013, Journal of pharmaceutical sciences.

[91]  Taravat Ghafourian,et al.  QSAR models for the prediction of plasma protein binding. , 2013, BioImpacts : BI.

[92]  Vijay K. Agrawal,et al.  Quantitative structure-pharmacokinetic relationship (QSPkP) analysis of the volume of distribution values of anti-infective agents from j group of the ATC classification in humans , 2012, Acta pharmaceutica.

[93]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[94]  Jin Y. Jin,et al.  A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer , 2013, Biopharmaceutics & drug disposition.

[95]  P. Rutgeerts,et al.  Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. , 1997, Gut.

[96]  Irini A. Doytchinova,et al.  Quantitative structure--clearance relationships of acidic drugs. , 2013, Molecular pharmaceutics.

[97]  Maurice Dickins,et al.  Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.

[98]  A A Kousba,et al.  Physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus pesticide diazinon. , 2004, Neurotoxicology.

[99]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds , 2018, Drug Metabolism and Disposition.

[100]  C Timchalk,et al.  A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.